US Patent

US12121506 — Artesunate powders, pharmaceutical compositions and methods of manufacture

Formulation · Assigned to Amivas Inc · Expires 2044-02-16 · 18y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for manufacturing and compositions of artesunate powders that can be easily sterilized and packaged.

USPTO Abstract

Disclosed herein are powders including a therapeutically effective amount of 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0 4,13 .0 8,13 ]1exadecane-10-yl]oxy]butanoic acid (artesunate) or a pharmaceutically acceptable salt thereof that can be easily manufactured, sterilized and packaged. Processes for producing these powders and pharmaceutical compositions containing these powders are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US12121506
Jurisdiction
US
Classification
Formulation
Expires
2044-02-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Amivas Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.